1. Home
  2. PHAR vs PLRX Comparison

PHAR vs PLRX Comparison

Compare PHAR & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$12.27

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Pliant Therapeutics Inc.

PLRX

Pliant Therapeutics Inc.

HOLD

Current Price

$1.13

Market Cap

74.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
PLRX
Founded
1988
2015
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
74.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
PHAR
PLRX
Price
$12.27
$1.13
Analyst Decision
Strong Buy
Hold
Analyst Count
3
4
Target Price
$38.33
$2.67
AVG Volume (30 Days)
10.1K
477.1K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.97
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.04
N/A
Revenue Next Year
$2.51
N/A
P/E Ratio
$3,041.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.54
$1.09
52 Week High
$21.34
$1.95

Technical Indicators

Market Signals
Indicator
PHAR
PLRX
Relative Strength Index (RSI) 31.36 32.48
Support Level $11.83 $1.10
Resistance Level $17.29 $1.37
Average True Range (ATR) 0.44 0.04
MACD -0.33 -0.01
Stochastic Oscillator 22.05 7.14

Price Performance

Historical Comparison
PHAR
PLRX

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Share on Social Networks: